These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7526475)

  • 1. Cost effectiveness in the management of benign prostatic hyperplasia: Italian data.
    Di Silverio F; D'Eramo G; Flammia GP; Sciarra A; Buscarini M; Mauro M; Sciarra F
    Minerva Urol Nefrol; 1994 Jun; 46(2):93-9. PubMed ID: 7526475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia.
    Ohsfeldt RL; Kreder KJ; Klein RW; Chrischilles EA
    J Manag Care Pharm; 2004; 10(5):412-22. PubMed ID: 15369424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economics of different treatment options of benign prostatic hyperplasia in Turkey.
    Ilker Y; Tarcan T; Akdaş A
    Int Urol Nephrol; 1996; 28(4):525-8. PubMed ID: 9119638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia.
    DiSantostefano RL; Biddle AK; Lavelle JP
    BJU Int; 2006 May; 97(5):1007-16. PubMed ID: 16542339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical therapy versus transurethral resection of the prostate (TURP) for the treatment of symptomatic benign prostatic enlargement (BPE): a cost minimisation analysis.
    Davis NF; Jack GS; Witjes WP; Bjartell A; Caris C; Patel A; de la Taille A; Lawrentschuk N; Bolton DM; Tubaro A
    World J Urol; 2019 May; 37(5):873-878. PubMed ID: 30145778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia.
    Lowe FC; McDaniel RL; Chmiel JJ; Hillman AL
    Urology; 1995 Oct; 46(4):477-83. PubMed ID: 7571214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of symptomatic BPH in Italy: who is treated and how?
    Tubaro A; Montanari E
    Eur Urol; 1999; 36 Suppl 3():28-32. PubMed ID: 10559628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term cost comparison between surgical and medical therapy for benign prostatic hyperplasia: a study using hospital billing data.
    Ahn HS; Kim SJ; Choi JB; Choo SH; Shim KH; Kim SI
    BJU Int; 2019 May; 123(5A):E79-E85. PubMed ID: 30303597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia.
    McDonald H; Hux M; Brisson M; Bernard L; Nickel JC
    Can J Urol; 2004 Aug; 11(4):2327-40. PubMed ID: 15380054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacoeconomic analysis of patients with symptoms of benign prostatic hyperplasia.
    Cockrum PC; Finder SF; Ries AJ; Potyk RP
    Pharmacoeconomics; 1997 Jun; 11(6):550-65. PubMed ID: 10168095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Annual costs of benign prostatic hyperplasia in New Zealand.
    Scott WG; Scott HM
    Pharmacoeconomics; 1993 Dec; 4(6):455-68. PubMed ID: 10151048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term cost analysis of treatment options for benign prostatic hyperplasia in Norway.
    Johansen TE; Istad JA
    Scand J Urol Nephrol; 2007; 41(2):124-31. PubMed ID: 17454951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of treatment for benign prostatic hyperplasia: an economic model for comparison of medical, minimally invasive, and surgical therapy.
    Manyak MJ; Ackerman SJ; Blute ML; Rein AL; Buesterien K; Sullivan EM; Tanio CP; Strauss MJ
    J Endourol; 2002 Feb; 16(1):51-6. PubMed ID: 11890452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of medical treatment of benign prostatic hyperplasia in the Brazilian public health system.
    Bahia LR; Araujo DV; Pepe C; Trindade M; Camargo CM; Javaroni V
    Int Braz J Urol; 2012; 38(5):595-605. PubMed ID: 23131517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic costs of benign prostatic hyperplasia in the private sector.
    Saigal CS; Joyce G
    J Urol; 2005 Apr; 173(4):1309-13. PubMed ID: 15758787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An economic evaluation of finasteride for treatment of benign prostatic hyperplasia.
    Baladi JF; Menon D; Otten N
    Pharmacoeconomics; 1996 May; 9(5):443-54. PubMed ID: 10160256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost consequences of surveillance, medical management or surgery for benign prostatic hyperplasia.
    Chirikos TN; Sanford E
    J Urol; 1996 Apr; 155(4):1311-6. PubMed ID: 8632563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The economics of benign prostatic hyperplasia treatment: a literature review.
    Kortt MA; Bootman JL
    Clin Ther; 1996; 18(6):1227-41. PubMed ID: 9001839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost Comparison of Benign Prostatic Hyperplasia Treatment Options.
    DeWitt-Foy ME; Gill BC; Ulchaker JC
    Curr Urol Rep; 2019 Jun; 20(8):45. PubMed ID: 31218458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs of Managing Benign Prostatic Hyperplasia in the Office and Operating Room.
    Gill BC; Ulchaker JC
    Curr Urol Rep; 2018 Jul; 19(9):72. PubMed ID: 30022307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.